Pharmacyclics, Inc. (NASDAQ:PCYC)

CAPS Rating: 2 out of 5

A pharmaceutical company focused on the development of products that improve existing therapeutic approaches to cancer and other diseases.

Recs

1
Player Avatar lewrose (83.85) Submitted: 12/23/2012 1:37:57 PM : Outperform Start Price: $60.25 PCYC Score: +62.08

Game changing medication for several forms of leukemia, including CLL, about to be approved by FDA.

Featured Broker Partners


Advertisement